Compounds > lipoxin a4

lipoxin a4 and Diabetes Mellitus, Adult-Onset

lipoxin a4 has been researched along with Diabetes Mellitus, Adult-Onset in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (90.91)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Dong, C; Jing, Y; Li, M; Liu, B; Qian, X; Shen, C; Sun, Q; Wang, J; Wang, S; Zhang, K; Zhou, H1
Bathina, S; Das, UN2
Das, UN; Gundala, NKV; Naidu, VGM2
Das, UN1
Angayarkanni, N; Arif Mulla, M; Das, UN; Jithu, M; Kaviarasan, K; Sharma, T; Sivasankar, S1
Dain, A; Das, UN; Diaz-Gerevini, GT; Eynard, AR; Repossi, G; Tarres, MC1
Bajaj, M; Birnbaum, Y; Gutierrez, AD; Konduru, S; Sathyanarayana, P; Ye, Y1
Bajaj, M; Birnbaum, Y; Castillo, AC; Ling, S; Perez-Polo, JR; Qian, J; Ye, H; Ye, Y2

Reviews

2 review(s) available for lipoxin a4 and Diabetes Mellitus, Adult-Onset

ArticleYear
Vitamin C for Type 2 Diabetes Mellitus and Hypertension.
    Archives of medical research, 2019, Volume: 50, Issue:2

    Topics: Alprostadil; Ascorbic Acid; Cytoprotection; Diabetes Mellitus, Type 2; Dietary Supplements; Epoprostenol; Fatty Acids, Essential; Humans; Hyperglycemia; Hypertension; Lipoxins; Nitric Oxide; Pancreas

2019
Beneficial action of resveratrol: How and why?
    Nutrition (Burbank, Los Angeles County, Calif.), 2016, Volume: 32, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Autistic Disorder; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Proliferation; Cytochrome P-450 CYP1A1; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Gastrointestinal Tract; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-17; Lipoxins; Metabolic Syndrome; NF-kappa B; Resveratrol; Stilbenes; Transcription Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2016

Trials

1 trial(s) available for lipoxin a4 and Diabetes Mellitus, Adult-Onset

ArticleYear
The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.
    Atherosclerosis, 2012, Volume: 223, Issue:1

    Topics: Adiponectin; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoxins; Male; Middle Aged; Pioglitazone; Texas; Thiazolidinediones; Time Factors; Treatment Outcome; Up-Regulation

2012

Other Studies

8 other study(ies) available for lipoxin a4 and Diabetes Mellitus, Adult-Onset

ArticleYear
The protective effects of lipoxin A4 on type 2 diabetes mellitus: A Chinese prospective cohort study.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Animals; Cohort Studies; Diabetes Mellitus, Type 2; East Asian People; Humans; Prospective Studies

2023
PUFAs, BDNF and lipoxin A4 inhibit chemical-induced cytotoxicity of RIN5F cells in vitro and streptozotocin-induced type 2 diabetes mellitus in vivo.
    Lipids in health and disease, 2019, Dec-10, Volume: 18, Issue:1

    Topics: Alloxan; Animals; Arachidonic Acid; Benzo(a)pyrene; Brain-Derived Neurotrophic Factor; Cell Death; Cell Line, Tumor; Cytotoxins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Doxorubicin; Drug Interactions; Fatty Acids, Unsaturated; Insulin-Secreting Cells; Insulinoma; Lipoxins; Pancreatic Neoplasms; Rats; Rats, Wistar; Streptozocin

2019
Amelioration of streptozotocin-induced type 2 diabetes mellitus in Wistar rats by arachidonic acid.
    Biochemical and biophysical research communications, 2018, 01-29, Volume: 496, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Cytokines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Hypoglycemic Agents; Inflammation Mediators; Lipoxins; Male; Rats; Rats, Wistar; Streptozocin; Treatment Outcome

2018
Dysregulation of PI3K-Akt-mTOR pathway in brain of streptozotocin-induced type 2 diabetes mellitus in Wistar rats.
    Lipids in health and disease, 2018, Jul-24, Volume: 17, Issue:1

    Topics: Animals; Brain; Brain-Derived Neurotrophic Factor; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression Regulation; Lipoxins; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Wistar; Serine; Streptozocin; TOR Serine-Threonine Kinases

2018
Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance are potential risk factors for diabetic retinopathy.
    Metabolism: clinical and experimental, 2015, Volume: 64, Issue:9

    Topics: Adult; Aged; Brain-Derived Neurotrophic Factor; Case-Control Studies; Cell Line; Cytokines; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Humans; In Vitro Techniques; Lipopolysaccharides; Lipoxins; Male; Middle Aged; Prospective Studies; Retina; Risk Factors; Th1-Th2 Balance; Vascular Endothelial Growth Factor A

2015
Arachidonic acid and lipoxinA4 attenuate streptozotocin-induced cytotoxicity to RIN5 F cells in vitro and type 1 and type 2 diabetes mellitus in vivo.
    Nutrition (Burbank, Los Angeles County, Calif.), 2017, Volume: 35

    Topics: Animals; Apoptosis; Arachidonic Acid; Blood Glucose; Cell Line; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Eicosapentaenoic Acid; gamma-Linolenic Acid; Glucose Transporter Type 2; Homeodomain Proteins; Lipoxins; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide Synthase Type II; Pancreas; Rats; Rats, Wistar; Trans-Activators; Tumor Necrosis Factor-alpha

2017
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:6

    Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunoblotting; Lipids; Lipoxins; Male; Membrane Proteins; Mice; Myocardial Infarction; Myocardium; Phosphodiesterase 3 Inhibitors; PTEN Phosphohydrolase; Tetrazoles; Triazoles

2012
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
    American journal of physiology. Heart and circulatory physiology, 2013, Jan-01, Volume: 304, Issue:1

    Topics: Animals; Blood Glucose; Blotting, Western; Cholesterol; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Activation; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Isoquinolines; Lipoxins; Male; Mice; Myocardial Infarction; Myocardium; Peptides; Phosphodiesterase 3 Inhibitors; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Receptors, Glucagon; Signal Transduction; Sulfonamides; Tetrazoles; Triglycerides; Up-Regulation; Venoms

2013